134 related articles for article (PubMed ID: 24751319)
21. Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome.
Farabaugh AH; Bitran S; Witte J; Alpert J; Chuzi S; Clain AJ; Baer L; Fava M; McGrath PJ; Dording C; Mischoulon D; Papakostas GI
Int Clin Psychopharmacol; 2010 Jul; 25(4):214-7. PubMed ID: 20400905
[TBL] [Abstract][Full Text] [Related]
22. Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine.
Cassano P; Soares CN; Cohen LS; Lyster AK; Fava M
Arch Womens Ment Health; 2004 Jul; 7(3):167-71. PubMed ID: 15241662
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial.
Strik JJ; Honig A; Lousberg R; Lousberg AH; Cheriex EC; Tuynman-Qua HG; Kuijpers PM; Wellens HJ; Van Praag HM
Psychosom Med; 2000; 62(6):783-9. PubMed ID: 11138997
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Lam RW; Levitt AJ; Levitan RD; Michalak EE; Cheung AH; Morehouse R; Ramasubbu R; Yatham LN; Tam EM
JAMA Psychiatry; 2016 Jan; 73(1):56-63. PubMed ID: 26580307
[TBL] [Abstract][Full Text] [Related]
25. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
[TBL] [Abstract][Full Text] [Related]
26. The impact of medical comorbidity on acute treatment in major depressive disorder.
Iosifescu DV; Nierenberg AA; Alpert JE; Smith M; Bitran S; Dording C; Fava M
Am J Psychiatry; 2003 Dec; 160(12):2122-7. PubMed ID: 14638581
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.
Versiani M; Moreno R; Ramakers-van Moorsel CJ; Schutte AJ;
CNS Drugs; 2005; 19(2):137-46. PubMed ID: 15697327
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of prolonged-release trazodone in major depressive disorder: a multicenter, randomized, double-blind, flexible-dose trial.
Zhang L; Xie WW; Li LH; Zhang HG; Wang G; Chen DC; Cao Y; Cui LJ; Zhang KR; Shi JG; Tan QR; Zheng HB; Xu XF; Cheng ZH; Zhao JP
Pharmacology; 2014; 94(5-6):199-206. PubMed ID: 25376160
[TBL] [Abstract][Full Text] [Related]
29. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
[TBL] [Abstract][Full Text] [Related]
30. Percentage reduction of depression severity versus absolute severity after initial weeks of treatment to predict final response or remission.
Lin CH; Chen CC; Wang FC; Lane HY
Psychiatry Clin Neurosci; 2013 May; 67(4):265-72. PubMed ID: 23683158
[TBL] [Abstract][Full Text] [Related]
31. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients.
Wehmeier PM; Kluge M; Maras A; Riemann D; Berger M; Kohnen R; Dittmann RW; Gattaz WF
Pharmacopsychiatry; 2005 Jan; 38(1):13-6. PubMed ID: 15706460
[TBL] [Abstract][Full Text] [Related]
32. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
Amini H; Aghayan S; Jalili SA; Akhondzadeh S; Yahyazadeh O; Pakravan-Nejad M
J Clin Pharm Ther; 2005 Apr; 30(2):133-8. PubMed ID: 15811165
[TBL] [Abstract][Full Text] [Related]
33. Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group.
Small GW; Birkett M; Meyers BS; Koran LM; Bystritsky A; Nemeroff CB
J Am Geriatr Soc; 1996 Oct; 44(10):1220-5. PubMed ID: 8856002
[TBL] [Abstract][Full Text] [Related]
34. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
35. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
Papakostas GI; Petersen T; Homberger CH; Green CH; Smith J; Alpert JE; Fava M
Ann Clin Psychiatry; 2007; 19(1):5-8. PubMed ID: 17453655
[TBL] [Abstract][Full Text] [Related]
36. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
[TBL] [Abstract][Full Text] [Related]
37. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.
Sheehan DV; Harnett-Sheehan K; Spann ME; Thompson HF; Prakash A
Int Clin Psychopharmacol; 2011 Mar; 26(2):75-83. PubMed ID: 21102344
[TBL] [Abstract][Full Text] [Related]
38. Fluoxetine once every third day in the treatment of major depressive disorder.
Tural U; Onder E
Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120
[TBL] [Abstract][Full Text] [Related]
39. Body mass index (BMI) in major depressive disorder and its effects on depressive symptomatology and antidepressant response.
Dreimüller N; Lieb K; Tadić A; Engelmann J; Wollschläger D; Wagner S
J Affect Disord; 2019 Sep; 256():524-531. PubMed ID: 31280076
[TBL] [Abstract][Full Text] [Related]
40. Trajectories of depression symptom improvement and associated predictor analysis: An analysis of duloxetine in double-blind placebo-controlled trials.
Tokuoka H; Takahashi H; Ozeki A; Kuga A; Yoshikawa A; Tsuji T; Wohlreich MM
J Affect Disord; 2016 May; 196():171-80. PubMed ID: 26922146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
